Find a Doctor or Practice Location

Are you a referring physician?
I am searching for a
Reset Form
Adam D. Cohen, MD

Adam D. Cohen, MD Physician

Director, Myeloma Immunotherapy
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania

Dr. Cohen is a Penn Medicine employed physician.

Clinical Specialties


  • Hematology
  • Medical Oncology

Programs & Centers:

Board Certification:

  • Hematology, 2007
  • Medical Oncology, 2005

Clinical Expertise:

  • Autologous Stem Cell Transplantation
  • Lymphoma
  • Multiple Myeloma
  • Waldenstrom Macroglobulinemia (WM)

Description of Clinical Expertise

Multiple Myeloma
POEMS syndrome
Monoclonal gammopathies
Waldenstrom's Macroglobulinemia

Practice Locations and Appointments

  • Abramson Cancer Center

    Perelman Center for Advanced Medicine West Pavilion, 2nd Floor 3400 Civic Center Boulevard Philadelphia, PA 19104 800-789-PENN (7366)

    A facility of the Hospital of the University of Pennsylvania

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • CVS Health
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: University of Pennsylvania School of Medicine
Residency: Hospital of the University of Pennsylvania
Fellowship: Memorial Sloan-Kettering Cancer Center


American Association for Cancer Research, National American Society of Clinical Oncology, National American Society of Hematology, National Amyloidosis Support Group, Philadelphia Chapter, Local Eastern Cooperative Oncology Group, National Independent Response Adjudication Committee (IRAC), ACE-MM-102 trial (NCT01997840), International International Myeloma Society, International Managing Myeloma (educational resource), National Society for Immunotherapy of Cancer (SITC), National The Myeloma Beacon (a patient advocacy website), National

Hospital Affiliation

Dr. Cohen is a Penn Medicine employed physician.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.


Description of Research Expertise:

Cancer immunotherapy
Cellular therapy
Phase I trials

Selected Publications:

Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, Kaufman JL, Lentzsch S, Vogl DT, Gomes CL, Pascucci N, Smith DD, Orlowski RZ, Durie BG: Carfilzomib, pomalidomide, and dexamethasone (CPD) for relapsed or refractory myeloma. Blood 126 : 2284-90,2015.

Huntington SF, Weiss BM, Vogl DT, Cohen AD, Garfall AL, Mangan PA, Doshi JA, Stadtmauer EA.: Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. Lancet Haematology : e408-16,2015.

Paul TM, Liu SV, Chong EA, Luger SM, Porter DL, Schuster SJ, Tsai DE, Nasta SD, Loren A, Frey N, Perl A, Cohen AD, Weiss BM, Stadtmauer EA, Vogl DT.: Outpatient autologous stem cell transplantation for patients with myeloma. Clinical Lymphoma, Myeloma and Leukemia : 536-40,2015.

Garfall AL, Maus MV, Hwang W-T, Lacey SF, Mahnke YD, Melenhorst JJ, Zheng Z, Vogl DT, Cohen AD, Weiss BM, Dengel K, Kerr NDS, Bagg A, Levine BL, June CH: Chimeric antigen receptor T cells against CD19 for multiple myeloma. New England Journal of Medicine 373 : 1040-47,2015.

Benson DM, Cohen AD, Jagannath S, Munshi N, Spitzer G, Hofmeister CC, Efebera YA, Andre P, Zerbib R, Caligiuri MA: A phase I trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed/refractory multiple myeloma Clinical Cancer Research 21 (18): 4055-61,2015.

Lendvai NL*, Cohen AD*, Cho HJ: Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma Bone Marrow Transplantation 50 : 770-80,2015.

Waxman AJ, Mick R, Garfall AL, Cohen A, Vogl DT, Stadtmauer EA, Weiss BM.: Classifying ultra-high risk smoldering myeloma Leukemia 29 : 751-753,2015.

Garfall AL, Maus MV, Lacey SF, Mahnke YD, Melenhorst JJ, Zheng Z, Vogl DT, Cohen AD, Weiss BM, Dengel K, Kerr NDS, Hwang W-T, Levine B, June CH, Stadtmauer EA: Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR)-modified autologous T cells (CTL019) in advanced multiple myeloma. J Clin Oncol 33(suppl; abstr 8517) : 2015.

Cohen AD, Liedtke M, Scott EC, Kaufman JL, Landau H, Vesole DH, Gasparetto C, Lentzsch S, Gomes CL, Rosenzweig M, Sanchorawala V, Smith DD, Comenzo R, Durie D.: Safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis Clinical Lymphoma, Leukemia and Myeloma: Proceedings from 15th International Myeloma Workshop 15 (Supplement 3): e59,2015.

Merlini G, Sanchorawala V, Zonder JA, Kukreti V, Schoenland SO, Jaccard A, Dispenzieri A, Cohen AD, Berg D, Yuan Z, Hui A-M, Palladini G, Comenzo RL: Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL) Blood (ASH Annual Meeting) : #3450,2014.

Academic Contact Info

Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-154
3400 Civic Center Blvd

Philadelphia, PA 19104
Phone: (215) 615-5853
Fax: (215) 615-5887
Patient appointments: 800-789-PENN (7366)